Vanderbilt-Ingram Cancer Center Archive — Page 20 of 28

Vanderbilt-Ingram website >

October 28, 2021

VICC’s Mayer departing to take new role with AstraZeneca

Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.

By Tom Wilemon
October 21, 2021

Study evaluates how environment impacts cancer risk

Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states.

By Tom Wilemon
Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.
October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

By Tom Wilemon
September 30, 2021

Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.

By Tom Wilemon
September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Tom Wilemon
September 23, 2021

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt’s Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.

By Tom Wilemon